Enzymatic Release of O-Glycosylated Protein
Since O-Glycosylation occurs in all domains of life, the enzymatic release of O-glycosylated protein is a key segment in glycomics research. CD BioGlyco integrates various advanced technologies to develop an efficient and accurate release strategy of O-glycosylated proteins. Welcome clients from all over the world to cooperate with us!
O-Glycosylated Protein
Glycoproteins are proteins that contain oligosaccharide chains (glycans) covalently linked to amino acid side chains. The most common types of glycoproteins are N-linked and O-linked glycoproteins, which differ by structural differences. Glycans are attached to specific amino acid residue side chains of proteins in a co-translational or post-translational manner, a process known as glycosylation. These post-translationally linked glycans have multiple roles, such as cell recognition, adhesion, signaling, and more. O-Glycosylation is a post-translational event in which the carbohydrate is covalently attached to the hydroxyl group of serine (Ser) or threonine (Thr). O-Glycosylation provides ligands for selectins, resists proteolysis, and is involved in recognition phenomena. O-Glycoproteins change their glycosylation patterns when expressed in new cellular systems resulting in impaired protein function. In addition, O-glycosylation has implications for the biotechnology industry. Therefore, it is of interest to know the location and type of O-glycosylation in a given glycoprotein.
Various forms of O-glycosylation are abundant in organisms and play important roles in many cellular functions. Changes in O-glycosylation are also closely associated with a variety of diseases, such as Alzheimer's disease, diabetes, and cancer. O-Glycosylation changing of Mucin 1 (MUC1) is one of the striking features of oncogenic mucins. Studies have shown that the cancer-associated glycoform of MUC1 contributes to the progression, invasion, and metastasis of epithelial tumors. In conclusion, understanding these O-glycosylation changes in cancer cells may lead to new diagnostic and therapeutic opportunities.
Key Technologies
- High-throughput sample preparation: Process many samples simultaneously, efficiently, and with minimal manual intervention.
- Solid-phase extraction (SPE): Following enzymatic release, the sample contains a complex mixture of the now-free glycans, the deglycosylated protein, and the enzyme itself. SPE is a purification technique used to isolate the glycans of interest from this mixture.
- Size-exclusion chromatography (SEC): Used as a final cleanup step to ensure that the sample is free from any high-molecular-weight contaminants that could interfere with subsequent analyses.
Enzymatic Release of O-Glycosylated Protein: Advanced Solutions for Glycoproteomics
To better understand these O-glycosylation changes in cancer cells, a reliable method must be identified to separate O-glycosylated proteins from native glycoproteins before analysis. At CD BioGlyco, we have developed an advanced Enzymatic Release platform. We provide clients with efficient and accurate release services of native mucin-type O-glycosylated proteins via O-protease. We high-specifically hydrolyze peptide bonds in proteins at the N-terminus of O-glycans at Ser or Thr to release intact native core 1 O-glycosylated proteins. In addition, we provide clients with fast and sensitive O-glycosylated protein characterization services.
Fig.1 The process of enzymatic release of O-glycosylated protein. (CD BioGlyco)
- Sample Preparation
Upon receipt, samples undergo thorough quality assessment to determine protein concentration, purity, and initial glycosylation status.
- Enzymatic Digestion
A customized enzyme cocktail is selected based on the target O-glycan type and protein properties. The reaction is then performed at optimized temperature, pH, and incubation time to ensure efficient and complete release of O-glycosylated proteins.
- Glycan and Protein Separation
After enzymatic digestion, the released O-glycans are separated from the deglycosylated protein and residual byproducts using techniques such as solid phase extraction (SPE) or filtration to obtain highly purified released glycosylated fractions.
- Glycan Derivatization
To enhance detection signals by mass spectrometry (MS) or chromatography, glycans are labeled with 2-aminobenzamide (2-AB), 2-aminopyridine (2-AP), or permethylation to improve ionization efficiency and chromatographic resolution, resulting in more sensitive and accurate analytical results.
- Downstream Glycan Analysis
Structural elucidation and quantification are performed using high-resolution mass spectrometry (MS), while separation and relative quantification are performed using high-performance liquid chromatography (HPLC).
Workflow
Publication Data
Journal: Cells
IF: 5.2
Published: 2024
Results: This paper explores glycosylation in depth and emphasizes its importance in biological processes and its potential as a disease biomarker. The article details the characteristics of O-glycosylation, including the various original sugars and core structures, as well as the difficulty in predicting O-glycosylation sites due to the lack of clear protein sequence binding motifs. The article also touches on the interaction between N-glycosylation and O-glycosylation, and their combined effects on cellular function, immune response, and biotherapeutic properties. Finally, the article emphasizes the urgent need to fully characterize O-glycoproteins to understand their functional and structural roles.
Applications
- Identifying novel O-glycosylation-based biomarkers for early disease detection, progression monitoring, and therapeutic response prediction in conditions such as cancer, inflammatory diseases, and neurological disorders.
- Characterizing O-glycosylation patterns of therapeutic proteins (e.g., antibodies, fusion proteins) to ensure product quality, efficacy, and safety.
- Investigating the role of O-glycosylation in pathological processes, including host-pathogen interactions, immune evasion, and cellular signaling pathways, provides insights into disease pathogenesis.
Advantages
- Our proprietary enzyme panels and optimized protocols ensure highly specific and efficient release of O-glycans, minimizing non-specific cleavage and maximizing glycan yield.
- We prioritize methods that maintain the native structure of released glycans, preventing desialylation, degradation, or rearrangement.
- Beyond enzymatic release, CD BioGlyco offers a full suite of downstream glycan analysis services, including advanced MS and chromatography.
Frequently Asked Questions
CD BioGlyco is your trusted partner in glycobiology research, offering a comprehensive suite of services from the enzymatic release of O-glycosylated proteins to advanced glycan analysis and complementary solutions. Please feel free to contact us to discuss your specific project needs and provide tailored solutions.
Associated Services
Reference
- Helms, A.; Brodbelt, J.S. Mass spectrometry strategies for O-glycoproteomics. Cells. 2024, 13(5): 394. (Open Access)
- Glyco™ Synthesis Platform
- Custom Glycoprotein Synthesis
- Custom Glycoside Synthesis
- Custom Glycosyl Donor Synthesis
- Custom Thioglycoside Synthesis
- Custom Phosphatidylinositol Synthesis
- Custom Cyclodextrin Synthesis
- Custom Rhamnolipid Synthesis
- Custom Sphingolipid Synthesis
- Custom Building Block Synthesis
- Carbohydrate Manufacturing
- Synthesis Process Development and Optimization
- Custom Carbohydrate Synthesis
- Custom Glycolipid Synthesis
- Custom Glycopeptide Synthesis
- Custom Glycoconjugate Synthesis
- Custom Sugar-Nucleotide Synthesis
- Nucleoside & Nucleotide Synthesis Service
- Custom Oligonucleotide Synthesis Service
- Polynucleotide Synthesis Service
- Nucleoside & Nucleotide Modification Service
- Oligonucleotide Modification Service
- Nucleoside-based Production Service
- Nucleotide-based Production Service
- OPME-based NDP-sugar Synthesis Service
- OPME-based NMP-sugar Synthesis Service
- Glycomics Platform
- Glycoproteomics Platform
- N-Glycoproteomics of PDX Models
- Nanotechnologies for the Detection of Glycopeptides
- Glycoprotein Enrichment
- Glycoprotein Quantification
- Glyco-biomarker Detection Service
- Glyco-biomarker AFP Detection Service
- Glyco-biomarker CA19-9 Detection Service
- Glyco-biomarker CA125 Detection Service
- Glyco-biomarker CA15–3 Detection Service
- Glyco-biomarker CEA Detection Service
- Glyco-biomarker PSA Detection Service
- Glyco-biomarker Immunoglobulin G (IgG) Detection Service
- Glyco-biomarker Haptoglobin (Hp) Detection Service
- Glyco-biomarker α1-Antitrypsin (A1AT) Detection Service
- Glyco-biomarker α1-Acid Glycoprotein (AGP) Detection Service
- Glyco-biomarker Ceruloplasmin (CP) Detection Service
- Glyco-biomarker Fetuin A Detection Service
- Site Occupation
- Glycoprotein Structure Analysis
- Glycosylation Site-specific Antibody-Drug Conjugate (ADC) Development Platform
- Carbohydrate-based Glycomedicine Development Platform
- By Sources of Carbohydrate
- By Types of Carbohydrate
- Monosaccharides-based Glycomedicine Development
- Disaccharides-based Glycomedicine Development
- Trisaccharides-based Glycomedicine Development
- Oligosaccharides-based Glycomedicine Development
- Polysaccharides-based Glycomedicine Development
- Glycosides-based Glycomedicine Development
- Glycopeptide-based Glycomedicine Development
- Glycomimetic-based Glycomedicine Development
- By Applications of-based Glycomedicines
- Carbohydrate-based Anticoagulant Glycomedicine Development
- Carbohydrate-based Cardiovascular Glycomedicine Development
- Carbohydrate-based Antitumor Glycomedicine Development
- Carbohydrate-based Antidiabetic Glycomedicine Development
- Carbohydrate-based Antibacterial Glycomedicine Development
- Carbohydrate-based Antiviral Glycomedicines Development
- Carbohydrate-based Antiparasiti Glycomedicine Development
- By Discovery Strategies
- Glycoengineering-based Glycomedicine Development
- Production of Food Ingredients
- Multi-omics Platform for Cancer Glucose Metabolism (MOPCGM)
- Cancer Cell Glycolytic Analysis
- Cancer Cell TCA Cycle Analysis
- Cancer Cell PPP Analysis
- Gene-level Regulation Analysis of Cancer Glucose Metabolism
- Interplay Between Glucose Metabolism Reprogramming and Tumorigenesis & Progression
- Interplay Between Glucose Metabolism Reprogramming and Proliferative Signaling
- Interplay Between Glucose Metabolism Reprogramming and Growth Suppressor
- Interplay Between Glucose Metabolism Reprogramming and Cancer Cell Death
- Interplay Between Glucose Metabolism Reprogramming and Replicative Immortality
- Interplay Between Glucose Metabolism Reprogramming and Angiogenesis
- Interplay Between Glucose Metabolism Reprogramming and Invasion & Metastasis
- Interplay Between Glucose Metabolism Reprogramming and Immune Escape
- Interplay Between Glucose Metabolism Reprogramming and Genomic Instability
- Interplay Between Glucose Metabolism Reprogramming and Tumor-associated Inflammation
- Glucose Metabolism-Microenvironment Crosstalk Analysis in Cancer
- Cancer Glucose Metabolism In Vivo Analysis
- Applications of Studing Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism Small Molecule Inhibitor
- Discovery of Cancer Glucose Metabolism Therapeutic Monoclonal Antibodies
- Development of Gene Therapy Targeting Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism CAR-T Therapy Targeting
- Discovery of Cancer Glucose Metabolism Combination Therapy Strategy
- Discovery of Cancer Glucose Metabolism Precision Therapeutic Strategies
- Glycoengineering Platform
- Therapeutic Nucleic Acid Development Platform
- Therapeutic Oligonucleotide Synthesis Service
- siRNA Synthesis
- miRNA Synthesis
- ASO Synthesis
- Aptamer Synthesis
- PMO Synthesis
- sgRNA Synthesis
- Circular RNA Synthesis
- PNA Synthesis
- Lipid-based GalNac-RNA Delivery Service
- CpG Oligonucleotide Synthesis
- Click-based GalNac-RNA Delivery Service
- AntimiR Synthesis
- GalNAc-siRNA Delivery Service
- tRNA Synthesis
- GalNAc-ASO Delivery Service
- saRNA Synthesis
- Reporter Gene mRNA Synthesis
- Gene Editing mRNA Synthesis
- Gene Replacement mRNA Synthesis
- Cre Recombinase mRNA Synthesis
- hEPO mRNA Synthesis
- OVA mRNA Synthesis
- Therapeutic Oligonucleotide Modification Service
- Therapeutic Oligonucleotide Delivery Development Service
- Targeted Ligand and Linker Synthesis
- Monoantennary GalNac-RNA Delivery
- Biantennary GalNac-RNA Delivery
- Triantennary GalNac-RNA Delivery
- Tetra-antennary GalNac-RNA Delivery
- Solution Phase-based GalNac-RNA Delivery
- Solid Phase-based GalNac-RNA Delivery
- mRNA Poly(A) Tail Length Analysis
- GalNAc-siRNA Delivery
- GalNAc-ASO Delivery
- GalNAc-miRNA Delivery
- GalNAc-Aptamer Delivery
- GalNAc-AntimiR Delivery
- GalNAc-mRNA Delivery
- GalNAc-PNA Delivery
- Peptide-Therapeutic Oligonucleotide Delivery
- LNP-Therapeutic Oligonucleotide Delivery
- PEG-Therapeutic Oligonucleotide Delivery
- Biological Evaluation Service for Therapeutic Oligonucleotide
- mRNA-based Vaccine Development Service
- mRNA Sequence Design&Optimization Service
- mRNA Integrity Analysis ServicemRNA Integrity Analysis Service
- mRNA Biodistribution Analysis Service
- DNA Template Preparation Service
- mRNA Purity Analysis Service
- T Cell Cytokine Secretion Analysis Service
- mRNA Modification Service
- mRNA Length Analysis Service
- mRNA Purification Service
- Neutralizing Antibody Assay Service
- mRNA-LNP Formulation and Encapsulation Service
- mRNA Structural Characterization
- mRNA Structural Characterization Service
- mRNA Bioanalysis Service
- mRNA Residual DNA Template Analysis Service
- mRNA Residual Double-Stranded RNA (dsRNA) Analysis Service
- mRNA Size Analysis Service
- mRNA Polydispersity Analysis Service
- mRNA Zeta Potential Analysis Service
- mRNA Lipid Composition Analysis Service
- Oligonucleotide Drug Process and Formulation Development Service
- RNA Drug Process and Formulation Development
- Therapeutic Oligonucleotide Synthesis Service
- Glycobiology Microarray Platform
- Glyco™ Vaccine Development Platform
- Carbohydrate-based Vaccine Development
- Polysaccharide Vaccine Development
- Tumor-Associated Carbohydrate Vaccine Development
- Glycoconjugate Vaccine Development
- Natural Carbohydrate-based Vaccine Development
- Semi-synthetic Carbohydrate-based Vaccine Development
- Fully Synthetic Carbohydrate-based Vaccine Development
- Carbohydrate-based Antibacterial Vaccine Development
- Carbohydrate-based Antifungal Vaccine Development
- Carbohydrate-based Antiparasitic Vaccine Development
- Carbohydrate-based Antiviral Vaccine Development
- Carbohydrate-based Anticancer Vaccine Development
- Carbohydrate-based Antihelmintic Vaccine Development
- Monovalent Carbohydrate-based Vaccine Development
- Polyvalent Carbohydrate-based Vaccine Development
- Carrier Protein Design Service
- Carbohydrate Conjugation Service for Vaccine Development
- Carbohydrate-based Adjuvant Development
- Lipopolysaccharide-based Adjuvant Development
- Bacterial Outer Membrane Vesicles (OMVs)-based Adjuvant Development
- Trehalose Glycolipid-based Adjuvant Development
- Galactosylceramide-based Adjuvant Development
- Peptidoglycan-based Adjuvant Development
- Chitin/Chitosan-based Adjuvant Development
- Inulin-based Adjuvant Development
- Mannans-based Adjuvant Development
- Alginate-based Adjuvant Development
- Saponin-based Adjuvant Development
- α-Glucan-based Adjuvant Development
- Lentinan-based Adjuvant Development
- β-Glucans-based Adjuvant Development
- Deltin-based Adjuvant Development
- Muramyldipeptide-based Adjuvant Development
- Cord Factor-based Adjuvant Development
- Zwitterionic Polysaccharide-based Adjuvant Development
- Novel Plant Polysaccharides-based Adjuvant Development
- Glycoprotein-based Vaccine Development
- Glycopeptide-based Vaccine Development
- Carbohydrate-based Vaccine Development
- Glycogenomics Platform
- Glycogene Editing Service
- Glycogene Delivery Service
- Glycogene Expression Profiling
- Cancer Glycogene Discovery Service
- Glycogene Discovery Service in Cervical Cancer
- Glycogene Discovery Service in Leukemia
- Glycogene Discovery Service in Bladder Cancer
- Glycogene Discovery Service in Colorectal Adenocarcinoma
- Glycogene Discovery Service in Liver Cancer
- Glycogene Discovery Service in Lymphoma
- Glycogene Discovery Service in Breast Cancer
- Glycogene Discovery Service in Prostate Cancer
- Glycogene Discovery Service in Pancreatic Cancer
- Glycogene Discovery Service in Lung Cancer
- Glycogene Discovery Service in Thyroid Cancer
- Glycogene Discovery Service in Ovarian Cancer
- Glycan Display Platform
- Traditional Glycan Display Array
- Natural Oligosaccharide Library Construction Service
- Chemical Synthesis-based Oligosaccharide Library Construction Service
- Enzymatic Synthesis-based Oligosaccharide Library Construction Service
- Modular Synthesis-based Oligosaccharide Library Construction Service
- Oligosaccharide Library Immobilization Service
- Cell-based Glycan Display Array
- Neoglycolipid (NGL) Display Array
- Liquid Glycan Display Array (LiGA)
- Glycophage Display
- N-linked Glycoprotein-based Glycophage Display System Construction Service
- O-linked Glycoprotein-based Glycophage Display System Construction Service
- Glycophage Display-based Glycosylase Genetic Analysis Service
- Glycophag Display-based Glycoarray Service
- Glycophage Display-based Antibody Development Service
- Glycophage Display-based Epitope Mapping Service
- Glycophage Display-based Biomarker Development Service
- De Novo Glycan Display
- Cell-Surface Glycan Editing
- Examining the Effects of Altering Blood Group Antigens on Erythrocyte Cell Surfaces
- Preventing Cellular Rejection During Transplantation
- Modulating Chemical Composition and Physical Parameters of Glycocalyx
- Tailoring Cell Membranes with Biologically Active Glycans
- Targeting Glycosaminoglycan-mediated Growth Factor Signaling to Influence Stem Cell Specification
- Long-term De Novo Glycan Display for Directing Stem Cell Fate
- Traditional Glycan Display Array
- GlycoNano™ Platform
- Glyconanoparticle Development Service
- Techniques for Glyconanoparticle Development
- Carbohydrate-based Nanoparticle Production
- Gold Glyconanoparticle Production
- Silver Glyconanoparticle
- Magnetic Glyconanoparticle
- Quantum Dot (QD) Glyconanoparticle
- Glyconanoparticle Characterization
- PEG Glyconanoparticle
- Carbon-based Glyconanoparticle
- Fluorescent Glyconanoparticle
- Silica Glyconanoparticle
- Liposome Glyconanoparticle
- Glycol Nanohydrogel Development
- Glycol Nanorod
- Glycol Nanotube
- Glycol Nanocrystal/Nanosheet/Nanosphere/Nanofiber
- Glyconanoparticle Preclinical Study
- Glyconanoparticle Formulation
- Glyconanotechnology-based Biosensor Development
- GlycoNano™ Bioink Production for 3D Printing
- Glyconanoparticle Development Service
- Glyco™ Synthesis Platform







